Acute respiratory distress syndrome associated with coronavirus infection is related to a cytokine storm with large interleukin 6 (ILâ€6) release. The ILâ€6â€receptor blocker tocilizumab may control the aberrant host immune response in COVIDâ€19 patients. In this pandemic, kidney transplant (KT) recipients are a highâ€risk population for severe infection and showed poor outcomes. We present a multicenter cohort study of 80 KT patients with severe COVIDâ€19 treated with tocilizumab during hospital admission.
|